Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against Mycobacterium tuberculosis H37Rv strain

References

• ParksTHillAVChapmanSJThe perpetual challenge of infectious diseasesN Engl J Med201236719022762339
   PubMedGoogle Scholar
• World Health OrganisationTB: a global emergencyGenevaWHO1994 Available from: http://apps.who.int/iris/bitstream/handle/10665/58749/WHO_TB_94.177.pdf?sequence=1&isAllowed=yAccessed May 1, 2014
   Google Scholar
• GolechhaMCan India be tuberculosis free by 2050?Lancet20153859965328329
   PubMed Web of Science ®Google Scholar
• ModlinRLBloomBRTB or not TB: that is no longer the questionSci Transl Med20135213213sr624285487
   PubMed Web of Science ®Google Scholar
• World Health OrganisationGlobal tuberculosis reportGenevaWHO2013 http://apps.who.int/iris/bitstream/handle/10665/91355/9789241564656_eng.pdf;jsessionid=19C24BC298D22ADE4F52713219CACE2D?sequence=1Accessed May 1, 2014
   Google Scholar
• BaxtLAGarza-MayersACGoldbergMBBacterial subversion of host innate immune pathwaysScience2013340613369770123661751
   PubMed Web of Science ®Google Scholar
• DiaconAHPatientiaRFVenterAEarly bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smearsAntimicrob Agents Chemother20075182994299617517849
   PubMed Web of Science ®Google Scholar
• Van IngenJAarnoutseREDonaldPRWhy do we use 600 mg of rifampicin in tuberculosis treatment?Clin Infect Dis2011529194199
   PubMed Web of Science ®Google Scholar
• BeckerCDressmanJBJungingerHEBiowaiver monographs for immediate release solid oral dosage forms: rifampicinJ Pharm Sci201099104215422720737629
   PubMedGoogle Scholar
• HartmannGHonikelKOKnüselFNüeschJThe specific inhibition of the DNA-directed RNA synthesis by rifamycinBiochim Biophys Acta196714538438444863911
   PubMedGoogle Scholar
• SchwarzCMehnertWSolid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterizationJ Microencapsul199916220521310080114
   PubMed Web of Science ®Google Scholar
• SeydelJKTono-okaSSchaperKJBockLWienckeMMode of action of isoniazid (INH). Short communication: isolation and identification of an analog of NAD from 3H-INH treated bacterial cellsArzneimittelforschung1976264477478182179
   PubMed Web of Science ®Google Scholar
• JohnssonKSchultzPMechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosisJ Am Chem Soc19941161674257426
   Web of Science ®Google Scholar
• ThiemerEKChemie des isoniazids [Chemistry of isoniazids]J Ber Borstel19563192424 French
   Google Scholar
• ThiemerEKBiochemie des isoniazids [Biochemistry of isoniazids]J Ber Borstel19574299509 French
   Google Scholar
• SeydelJKSchaperKJWempeECordesHPMode of action and quantitative structure-activity correlation of tuberculostatic drugs of the isonicotinic acid hydrazide typeJ Med Chem1976194483492817022
   PubMed Web of Science ®Google Scholar
• du ToitLCPillayVDanckwertsMPTuberculosis chemotherapy: current drug delivery approachesRespir Res20067111816984627
   PubMedGoogle Scholar
• GumboTLouieADezielMRConcentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampinAntimicrob Agents Chemother200751113781378817724157
   PubMed Web of Science ®Google Scholar
• ShishooCJShahSARathodISSavaleSSVoraMJImpaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulationInt J Pharm20012281–2536711576768
   PubMedGoogle Scholar
• SinghSMariappanTTShankarRSardaNSinghBA critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products and the likely solutions to the problemInt J Pharm20012281–251711576764
   PubMedGoogle Scholar
• GoldmanALBramanSSIsoniazid: a review with emphasis on adverse effectsChest197262171774339326
   PubMed Web of Science ®Google Scholar
• de FariaTJRomanMde SouzaNMAn isoniazid analogue promotes Mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophagesAntimicrob Agents Chemother20125652259226722330919
   PubMed Web of Science ®Google Scholar
• MonederoICamineroJAMDR-/XDR-TB management: what it was current standards and what is aheadExpert Rev Respir Med20093213314520477307
   PubMedGoogle Scholar
• GriffithsGNyströmBSableSBKhullerGKNanobead-based interventions for the treatment and prevention of tuberculosisNat Rev Microbiol201081182783420938454
   PubMed Web of Science ®Google Scholar
• TotiUSGuruBRHaliMTargeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticlesBiomaterials201132276606661321652065
   PubMed Web of Science ®Google Scholar
• ZhangLPornpattananangkuDHuCMHuangCMDevelopment of nanoparticles for antimicrobial drug deliveryCurr Med Chem201017658559420015030
   PubMed Web of Science ®Google Scholar
• SoutoEBMullerRHThe use of SLN and NLC as topical particulate carriers for imidazole antifungal agentsPharmazie200661543143716724541
   PubMed Web of Science ®Google Scholar
• ZhangLGuFXChanJMWangAZLangerRSFarokhzadOCNanoparticles in medicine: therapeutic applications and developmentsClin Pharmacol Ther200883576176917957183
   PubMed Web of Science ®Google Scholar
• WagnerVDullaartABockAKZweckAThe emerging nanomedicine landscapeNat Biotechnol2006241211121717033654
   PubMed Web of Science ®Google Scholar
• ReisCPNeufeldRJRibeiroAJVeigaFNanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticlesNanomedicine20062182117292111
   PubMed Web of Science ®Google Scholar
• ChimoteGBanerjeeREvaluation of antitubercular drug insertion into preformed dipalmitoyl-phosphatidylcholine monolayersColloids Surf B Biointerfaces200862225826418082382
   PubMedGoogle Scholar
• SomoskoviANovel laboratory diagnostic tests for tuberculosis and their potential role in an integrated and tiered laboratory networkTuberculosis (Edinb)201595Suppl 1S197S19925736539
   PubMedGoogle Scholar
• RNTCP response to challenges of drug resistant TB in India. Revised National Tuberculosis Control Program2012 Available from: https://tbcindia.gov.in/WriteReadData/l892s/8320929355Guidelines%20for%20PMDT%20in%20India%20-%20May%202012.pdfAccessed December 1, 2016
   Google Scholar
• HakkimaneSSGuruBRBiodegradable polymer nanoparticles of anti-tubercular drug: formulation and in vitro release studiesAdv Sci Lett201723317181723
   Google Scholar
• HakkimaneSSGuruBRNano formulation analysis: analytical method development of isoniazid and simultaneous estimation of anti-tubercular drugs isoniazid and rifampicin by RP-HPLCAsian J Pharm Clin Res2017105330335
   Google Scholar
• PatilYSadhukhaTMaLPanyamJNanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistanceJ Control Release20091361212919331851
   PubMed Web of Science ®Google Scholar
• SiddiqiSHRüsch-GerdesSMGIT™ Procedure Manual for BACTEC™ MGIT 960™ TB SystemGenevaFoundation for Innovative New Diagnostics (FIND)2006
   Google Scholar
• LawsonLEmenyonuNAbdurrahmanSTComparison of Mycobacterium tuberculosis drug susceptibility using solid and liquid culture in NigeriaBMC Res Notes2013621523721428
   PubMedGoogle Scholar
• WenZSLiuLJQuYLOuyangXKYangLYXuZRChitosan nanoparticles attenuate hydrogen peroxide-induced stress injury in mouse macrophage RAW264.7 cellsMar Drugs201311103582360024084781
   PubMed Web of Science ®Google Scholar
• DuttMKhullerGKChemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in poly (DL-lactide-co-glycolide) microparticlesJ Antimicrob Chemother200147682983511389115
   PubMed Web of Science ®Google Scholar
• MakinoKNakajimaTShikamuraMEfficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicinColloids Surf B Biointerfaces2004361354215261021
   PubMed Web of Science ®Google Scholar
• ItoFMakinoKPreparation and properties of monodispersed rifampicin-loaded poly(lactide-co-glycolide) microspheresColloids Surf B Biointerfaces2004391–2172115542335
   PubMed Web of Science ®Google Scholar
• CooperDLHarirforooshSDesign and optimization of PLGA-based diclofenac loaded nanoparticlesPLoS One201491e8732624489896
   PubMed Web of Science ®Google Scholar
• BhandariRKaurIPPharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticlesInt J Pharm20134411–220221223220081
   PubMed Web of Science ®Google Scholar
• BeheraAKBarikBBPandyaSJoshiSFormulation and evaluation of isoniazid loaded-Σ-polycaprolactone nanoparticlesJ Pharm Res201252798802
   Google Scholar
• RazakSAYacobSFFSAbdullahJMAdnanRIsoniazid and β-cyclodextrin complexes: a stability study in aqueous solutionJ Chem Pharm Res201577346355
   Google Scholar
• SahooSKPanyamJPrabhaSLabhasetwarVResidual polyvinyl alcohol associated with poly (D L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptakeJ Control Release200282110511412106981
   PubMed Web of Science ®Google Scholar
• PignatelloRRicuperoNBucoloCMaugeriFMalteseAPuglisiGPreparation and characterization of Eudragit Retard nanosuspensions for the ocular delivery of cloricromeneAAPS PharmSciTech20067117
   Web of Science ®Google Scholar
• GuFZhangLTeplyBAPrecise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymersProc Natl Acad Sci U S A200810572586259118272481
   PubMed Web of Science ®Google Scholar
• ZetasizerPCSTheory manual MAN 0152Issue 1.11.12.6MalvernMalvern Instruments Ltd1996
   Google Scholar
• WuLZhangJWatanabeWPhysical and chemical stability of drug nanoparticlesAdv Drug Deliv Rev201163645646921315781
   PubMed Web of Science ®Google Scholar
• ClogstonJDPatriAKZeta potential measurementMethods Mol Biol2011697637021116954
   PubMedGoogle Scholar
• ShishooCJShahSARathodISSavaleSSKotechaJSShahPBStability of rifampicin in dissolution medium in presence of isoniazidInt J Pharm1999190110912310528103
   PubMedGoogle Scholar
• SinghSMariappanTTShardaNSinghBDegradation of rifampicin isoniazid and pyrazinamide from prepared mixtures and marketed single and combination products under acid conditionsPharm Pharmacol Commun20006491494
   Google Scholar
• LewisDHControlled release of bioactive agents from lactide/glycolide polymersChasinMLangerRBiodegradable Polymers as Drug Delivery SystemsNew YorkMarcel Dekker Inc1990143
   Google Scholar
• MittalGSahanaDKBhardwajVRavi KumarMNEstradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behaviour in vitro and in vivoJ Control Release20071191778517349712
   PubMed Web of Science ®Google Scholar
• AhmadZMaqboolMRajaAFNanomedicine for tuberculosis: insights from animal modelsInt J Nano Dim2011216784
   Google Scholar
• NagaiSWikerHGHarboeMKinomotoMIsolation and partial characterization of major protein antigens in the culture fluid of Mycobacterium tuberculosisInfect Immun1991593723821898899
   PubMed Web of Science ®Google Scholar